| abstract |
The present invention relates to the use of at least one protease for the manufacture of a medicament for the treatment and/or prevention of benign prostate hypertrophy/hyperplasia, wherein the medicament is adapted for enteral administration, the at least one protease is selected from the group consisting of plant, non-mammalian animal and microbial proteases and the at least one protease is administered in an amount of 1 to 100 mg/kg body weight. |